Amneal Pharmaceuticals vs Jazz Pharmaceuticals
Jazz Pharmaceuticals is the larger business, with $4.27bn of revenue in fiscal 2025 against $3.02bn for Amneal Pharmaceuticals (1.4 times as much). Amneal Pharmaceuticals grew faster (8.0% against 4.9%). Amneal Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 2.4% against -8.3%.
| Latest fiscal year | Amneal PharmaceuticalsAMRX, 2025 | Jazz PharmaceuticalsJAZZ, 2025 |
|---|---|---|
| Revenue | $3.02bn | $4.27bn |
| Revenue growth | 8.0% | 4.9% |
| Net income | $72.1m | −$356m |
| Operating margin | 13.1% | -10.1% |
| Net margin | 2.4% | -8.3% |
| Return on equity | — | -8.5% |
| Free cash flow | $270m | $1.30bn |
| Cash | $282m | $1.39bn |
| Total debt | $2.69bn | $5.41bn |
| Debt to equity | — | 125.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $125m |
| Employees | 8,500 | 700 |
| Market value | $6.60bn | $15.09bn |
| Price vs our value range | Above our value range | Below our value range |
| Moat score | 34 (Weak) | 66 (Moderate) |
| Insider trades, 12 months | 0 buys, 7 sales | 0 buys, 59 sales |